Search Demo - PsychoGenics

To provide the best experiences, we use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.

Functional Always active

The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.

Preferences

The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.

Statistics

The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.

Marketing

The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.

Filters

Filters

Therapeutic Areas

Specific Disorders

Filters

A Novel Phenotypic Approach to CNS Drug Discovery

4 Next-Gen CNS Drug Development Trends

Why Psychogenics and Emyria are Collaborating to Examine MDMA-Inspired Compounds

PsychoGenics Announces Extension of Ongoing Drug Discovery Collaboration with Karuna Therapeutics

New Partnership May Give MDMA an Edge in the Psychedelics Space

Emyria Starts Program with Neuroscience Drug Discovery CRO

Clinical Catch-Up: Updates in Solid Tumors, ALS, Migraine and More

Emyria teams with CRO PsychoGenics for MDMA-like Drug Development

The GBA1 D409V Mutation Exacerbates Synuclein Pathology to Differing Extents in two Alpha-Synuclein Models

Let’s Find the Right Solution Together

Quick Links

Contact

Address

Email

Phone

Fax